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Abstract 
Delivering vaccine antigens to mucosal surfaces is potentially very attractive, especially as protection 
from mucosal infections may be mediated by local immune responses. However, to date mucosal 
immunisation has had limited successes, with issues of both safety and poor immunogenicity. One 
approach to improve immunogenicity is to develop adjuvants that are effective and safe at mucosal 
surfaces. Differences in immune responses between mice and men have overstated the value of 
some experimental adjuvants which have subsequently performed poorly in the clinic. Due to their 
closer similarity, non-human primates can provide a more accurate picture of adjuvant performance. 
In this study we immunised rhesus macaques (Macaca mulatta) using a unique matrix experimental 
design that maximised the numbers of adjuvants screened whilst reducing the animal usage. 
Macaques were immunised by the intranasal, sublingual and intrarectal routes with the model 
protein antigens keyhole limpet haemocyanin (KLH), β-galactosidase (β-Gal) and ovalbumin (OVA) in 
combination with the experimental adjuvants Poly(I:C), Pam3CSK4, chitosan, Thymic Stromal 
Lymphopoietin (TSLP), MPLA and R848 (Resiquimod). Of the routes used, only intranasal 
immunisation with KLH and R848 induced a detectable antibody response. When compared to 
intramuscular immunisation, intranasal administration gave slightly lower levels of antigen specific 
antibody in the plasma, but enhanced local responses. Following intranasal delivery of R848, we 
observed a mildly inflammatory response, but no difference to the control. From this we conclude 
that R848 is able to boost antibody responses to mucosally delivered antigen, without causing excess 
local inflammation. 
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Introduction 
Mucosal immunisation offers an attractive prospect for many of the more intractable infections for 
which we have yet to develop vaccines, especially those that infect via mucosal surfaces, such as 
HIV, RSV and tuberculosis. In principle, mucosal immunisation may lead to responses at the sites of 
infection – either the respiratory or the genital tracts, improving protective efficacy 1. However, 
immune responses to mucosally delivered antigens are often limited for various reasons including 
biochemical and mechanical degradation of the antigen, or immune tolerance at mucosal sites 2. An 
important consideration for the mucosal administration of vaccines is the selection of the route of 
administration. Whilst targeting the genital or rectal mucosa may theoretically induce more specific 
local responses, there are cultural, biomechanical and immunological reasons why these routes may 
not be the most effective. It has, however, been suggested that mucosal immunisation at one site 
can induce responses at other distal mucosal sites 3. Specifically, immunological linkage between the 
upper respiratory tract and lower genital tract has been proposed, based predominantly on studies 
performed in mice, 4. 
Another approach to overcome the poor immune response at mucosal sites is to develop effective 
mucosal adjuvants, reviewed in 5. To date there is no licensed adjuvant for mucosal use. Safety is of 
paramount importance as perturbations of the tightly regulated immune responses at mucosal 
surfaces can cause unwanted reactions 6. Likewise the proximity of the nervous system to mucosal 
surfaces can lead to complications such as Bell’s palsy 7. A number of adjuvants have been suggested 
and tested in mouse studies 8. Many of the adjuvants that have been tested have been based upon 
agents that are known ligands for toll like receptors (TLR), a highly conserved family of pattern 
recognition receptors that activate the innate immune response. Whilst the murine model is highly 
effective for the screening of compounds, there are limitations in the translation of these 
compounds from the mouse to humans. Non-human primates, because of their genetic proximity to 
man, larger size and the similarities in anatomy provide a more effective platform to confirm the 
efficacy of potential adjuvants. However, there are ethical considerations in the use of large 
numbers of these animals and approaches to reduce animal numbers are required.  
In the current study we used a matrix design to compare mucosal immunisation of three different 
antigens by the intranasal, sublingual or intrarectal routes in combination with six different 
experimental adjuvants Poly(I:C), Pam3CSK4, chitosan, Thymic Stromal Lymphopoietin (TSLP), MPLA 
and R848 (Resiquimod), in order to select the best adjuvant for future clinical trials. Of the 
combinations tested, only antigen delivered intranasally in combination with the TLR7/8 agonist 
R848 induced significant antibody responses. When the R848/ antigen combination was delivered by 
either the intramuscular or intranasal routes, intramuscular delivery induced greater systemic 
responses but intranasal delivery induced a slightly greater nasal response. In a separate study 
intranasal R848 gave a very similar cytokine and cell profile to intranasal PBS (control) except for a 
delayed TNF signal, suggesting that it is safe for intranasal delivery. In summary, R848 appears to be 
a highly effective in promoting local and systemic immune responses by the nasal route of 
administration. 
  
Results 
Intranasal but not other routes induce an immune response 
Macaques (Macaca mulatta) were immunised by the intranasal, sublingual and intrarectal routes 
with the model protein antigens keyhole limpet haemocyanin (KLH), β-galactosidase (β-Gal) or 
ovalbumin (OVA) in combination with the experimental adjuvants Pam3CSK4, Poly(I:C), Chitosan, 
Thymic Stromal Lymphopoietin (TSLP), Monophosphoryl Lipid A (MPLA) or Resiquimod (R848). 
Adjuvant selection was based on preclinical studies that identified Pam3CSK4 (TLR1/2), chitosan and 
TSLP as effective adjuvants in mice 8, 9. R848 was inefficient in the murine model but was seen to be 
effective in previous macaque studies 10 and was therefore selected as a comparator. This study was 
designed as a preliminary study to select adjuvants for future clinical studies and therefore a range 
of experimental adjuvants targeting a broad spectrum of pattern recognition receptors were 
selected. To maximise the screening potential of this study, different adjuvants were used at 
different sites. Different antigens were used to allow the overlapping study of the different routes of 
delivery whilst reducing animal usage, the antigens selected are common model antigens. 
In each vaccination group, four macaques were immunised with a range of antigens and adjuvants 
by the intranasal, sublingual and intrarectal routes (Table 2). No responses were detected in sera or 
mucosally after sublingual ovalbumin or intrarectal beta-galactosidase delivery (data not depicted). 
Intranasal immunisation with KLH in PBS alone, or co-administered with either Pam3CSK4 or 
chitosan, failed to induce any detectable local or systemic responses (Fig 1A). The lack of 
responsiveness in the presence of Pam3CSK4 or chitosan was in complete contrast to that seen in 
mice where they promoted a potent immune response. A single animal (IE71) in the TSLP group 
induced detectable but low systemic IgG and IgA (Fig 1B) responses with transient IgG responses in 
the vagina (Fig 1E) but not nasal mucosa (1 out of 4). Because they failed to induce a systemic IgG 
response further analysis was not performed on antigen alone, Pam3CSK4 or chitosan adjuvanted 
samples. 
Potent immune responses were induced on co-administration of KLH with R848 (Fig 1). Here 
systemic specific IgG levels (Fig 1A) one week after the third immunisation had reached mean titre of 
1.8x106 (+/- 2.6x106). Systemic specific IgA levels (Fig 1B) were lower with a mean titre of 4.9x103 
(+/- 1.3x103) at the same time point, one week after the final immunisation. In contrast, nasal 
specific IgG (Fig 1C) and IgA (Fig 1D) responses were equivalent. Vaginal specific IgG levels (Fig 1E) 
were higher than those for IgA (Fig 1F) reflecting the normal predominance of IgG in the lower 
genital tract. Sporadic specific IgG responses were observed in rectal secretions of 3/4 animals, 
rectal responses were low and not positive over concurrent weeks (data not shown). One animal 
(IF53) had detectable titres of rectal IgG over weeks 11-13 with a peak titre of 632 at week 12. Only 
one animal had detectable rectal antigen specific IgA (GK02) at a single time-point (Wk11) where it 
was also positive for IgG. No responses were detected in saliva collected sublingually. 
We measured KLH specific secretory IgA (scIgA) levels in nasal samples at weeks 0, 4, 14 and 15 
following immunisation with KLH. All animals in the R848 group showed induction of high levels of 
scIgA, in contrast the one animal in the TSLP group (IE71) that had shown a specific immune 
response to KLH immunisation showed lower levels of scIgA (Fig 1G). Direct comparison in specific 
scIgA and IgA cannot be made due to the different configuration of the two assays. Secretion rates 
of specific IgG and IgA were evaluated by calculation of their relative coefficients of excretion (RCE) 
relative to albumin levels. A theoretical value of 1 assumes equal distribution between serum and 
mucosal compartments. An RCE value significantly higher than 1 indicates that Ig detected in the 
secretion is locally produced or selectively transported from serum across the mucosal barrier (or 
both), but does not exclude that a part of the Ig detected is also transudated from serum 11. RCE 
values for nasal IgA and vaginal IgA levels were greater than 1 indicating that the IgA is either 
actively transported or locally produced (Fig 1H), supporting the scIgA data. From this we conclude 
that R848 was the most effective adjuvant of those tested when delivered intranasally. 
Comparison of responses induced by intramuscular and intranasal immunisation 
As intranasal immunisation using R848 as the adjuvant gave good local and systemic IgG and IgA 
responses, we decided to investigate how the responses would compare to intramuscular 
immunisation. Eight animals from the initial study that had no detectable KLH responses were 
randomised and reused. KLH and R848 were administered intranasally to 4 animals (IE58, IE60, IE63, 
IE64) and another 4 animals intramuscularly (IE57, IE59, IE61, IE62) at the same doses as above. 
Intramuscular immunisation with KLH and R848 resulted in consistently high titres for plasma IgG 
(Fig 2A) and IgA (Fig 2B), with titres reaching a peak two weeks after the second and third 
immunisation for IgG and two weeks after each immunisation for IgA. As seen before intranasal 
immunisation induced both antigen specific IgG (Fig 2C) and IgA (Fig 2D). Whilst intramuscular 
immunisation induced higher levels of KLH specific plasma IgG than intranasal (Fig 2E), similar levels 
of plasma IgA were observed (Fig 2F).  
We then examined specific IgG and IgA titres in nasal and vaginal samples from the same animals. 
Low levels of KLH specific nasal IgG was induced by both the intranasal (Fig 3A) and intramuscular 
routes (Fig 3B), the levels were similar between the two routes peaking after the third immunisation 
at week 8 (Fig 3C). Of note, specific IgA responses were considerably enhanced by IN immunisation, 
peaking after the 3rd immunisation, whereas IM immunisation failed to induce any IgA responses in 
nasal fluids (Fig 3E-G). Low levels of KLH specific vaginal IgG were induced by both the intranasal (Fig 
3I) and intramuscular routes (Fig 3J), the levels were similar between the two routes peaking after 
the third immunisation (Fig 3K). After IN immunisation, but not IM immunisation, the RCE for KLH 
specific nasal IgA (Fig 3H), but not nasal IgG (Fig 3D) or vaginal IgG (Fig 3L) was significantly greater 
than 1 for the IN immunised animals. 
R848 delivered intranasally induces mild local inflammatory response 
To assess safety, macaques were inoculated intranasally with R848 or PBS and nasal swabs collected 
after inoculation. Nasal swabs were examined for cellular infiltrates by flow cytometry and manual 
cytospin counts. The introduction of fluid alone (either PBS or R848) intranasally both lead to an 
acute recruitment of neutrophils (Fig 4A) and monocytes (Fig 4B), however the increase in 
neutrophils was greater with R848, peaking at 6 hours post immunisation. R848 also led to a slightly 
enhanced recruitment of CD3+ cells into the nasal airways over PBS alone, increasing to 96 hours 
after inoculation (Fig 4C). Nasal fluids were assessed for cytokine/chemokine responses by cytokine 
bead array (Fig 4D-I). Inoculation with fluid alone, and/or the repeat sampling appeared to induce an 
acute local response, regardless of the agent given. Similar responses were seen in R848 and PBS 
treated animals for IL-1β, CCL2, IL-6 and CXCL8, with an acute peak within 12 hours of exposure and 
then a return to baseline levels, matching the cell recruitment profile. Other mediators including IL-
2, CCL2 and GMCSF were undetectable (data not depicted). Only CCL5 and TNF followed a slightly 
different kinetic, with sustained detection of both after 24 hours, and a significantly greater level of 
TNF detectable in the R848 inoculated animals at 96 hours after inoculation. This suggests that R848 
induces a mild local inflammation above that induced by exposure to fluid alone in the nasal airway, 
which may contribute to the adjuvant activity.  
 
Discussion 
In this study we assessed a range of adjuvants for mucosal immunisation. We compared the 
adjuvants in combination with model antigens via a range of routes. Of the mucosal routes tested 
only intranasal immunisation induced an antibody response and this only occurred when R848 was 
used as an adjuvant. It is not clear why the other adjuvants did not boost the response, in a previous 
study chitosan did have a slight adjuvant effect in cynomologous monkeys 12, though a larger dose of 
both antigen (ovalbumin) and adjuvant was used, furthermore there was no statistical increase in 
antibody titre in the antigen plus chitosan groups 12. Chitosan is believed to act as an adjuvant 13 has 
been delivered in clinical trials intranasally with diphtheria 14 and Neisseria meningitidis serogroup C 
polysaccharide 15 boosting the response, but it may be that these antigens are more immunogenic 
than the ones used in the current study. TSLP has not been tested as an adjuvant in macaques 
before. One possibility for the absence of a strong adjuvant effect for TSLP in the macaques was that 
since recombinant human not macaque TSLP was used and there may be species specific 
differences, however one study has suggested that human TSLP can activate DC from cynomolgus 
macaques 16. 
Previous studies have investigated the role of R848 as a mucosal adjuvant in macaques using a prime 
boost regime 10, though it was not compared to antigen alone in the published study. A recently 
published study investigating the mechanism of R848 action after systemic delivery demonstrated 
that R848 led to the release of TNF by macrophages and neutrophils which in turn led to the 
maturation of Langerhans cells 17. In the current study we observed limited local inflammation after 
R848 compared to PBS alone. However, there was a trend towards increased neutrophil recruitment 
after intranasal R848 delivery and increased TNF at 96 hours after immunisation, which suggests a 
similar mechanism works at mucosal surfaces. Apart from the delayed TNF signature, R848 
administration gave a very similar cytokine profile to PBS alone, administration of fluid intranasally 
followed by repeat sampling led to an acute peak of pro-inflammatory cytokines and cells. In the 
current study, the R848 was given without antigen, a different profile may have been observed in 
the presence of antigen. These studies suggest that R848 is safe and it is currently in use in a number 
of clinical trials as a vaccine adjuvant and has been shown to have some effect in combination with 
GMCSF and Poly(I:C) when administered with a tumour antigen intradermally 18, it is also a licensed 
product for use as a topical cream (Resiquimod) which we have also previously shown induces 
increased TNF responses when administered intranasally to macaques 19. A study looking at oral 
administration to control Hepatitis C virus found adverse reactions in patients given 0.02mg/kg twice 
weekly for four weeks 20, in the current study we use a final dose equivalent to half the safe dose 
(0.5 mg total in the current study, equivalent to 0.005 mg/kg in the clinical study), this dose in mg/ 
kg of the macaque was considerably more than used in the previous human study, but for a single 
administration. Adverse effects from R848 (and other adjuvants) are most likely associated with 
inflammation and there is a critical balance (“the goldilocks effect”) required in adjuvants between 
unreactive and hyper inflammatory response. Thus, although R848 did not appear to be toxic in this 
study we cannot exclude hyper inflammatory responses and associated adverse effects when used 
at high doses in humans. 
We only saw responses following nasal immunisation, but not sublingual or intrarectal. To our 
knowledge this is the first study that has explored the use of sublingual vaccination in macaques 
using protein alone, though it has been used for DNA vaccines 21 and an Adenovirus-protein boost 
regime 22. Whilst sublingual delivery has been shown to be highly effective in small animal models 23, 
in our study, we saw no response following sublingual delivery of ovalbumin. It is possible that the 
success of sublingual delivery in the mouse system in some way reflective of the much smaller size of 
the murine mouth, and that the delivered antigen either coats a greater surface area of responsive 
cells, or is swallowed or recirculated to the adenoids or tonsillar lymphoid tissues at the back of the 
mouth. It is of note that most trials of sublingually delivered antigen are used in the context of 
immunotherapy with a view to induce tolerance 24. In a clinical trial sublingually delivered human 
papilloma virus vaccine only induced an immune response in 3 out of 12 volunteers 25. Intrarectal 
immunisation of macaques with peptides adjuvanted with heat labile entertoxin has been 
demonstrated to induce a cellular response 26, 27, but no responses were seen following intrarectal 
DNA immunisation 28, none of these studies assessed the antibody response. Intrarectal delivery of 
canarypox virus vaccines has been tested in a clinical trial, but failed to induce a response 29. Whilst 
intrarectal immunisation is a conceptually attractive route for the induction of local immune 
response for sexually transmitted and gastrointestinal infections, the lack of efficacy and possible 
issues around cultural acceptability could potentially rule this route out. Of the routes tested only 
intranasal delivered antigen induced an immune response, and the use of this route has been well 
explored in a range of pre-clinical and clinical studies and it is currently used for the delivery of live 
attenuated influenza vaccine. There are a number of possible reasons why intranasal is better than 
other mucosal routes for the induction of both local and systemic immune responses, including 
longer retention times than the rectal route (particularly in animal models), a kinder environment 
for protein antigens in terms of pH and digestive enzymes and a higher level of antigen presenting 
cells 6. The frequency and level of microbacterial colonisation in the different mucosal compartments 
may also contribute to the levels of immunosuppression at different mucosal surfaces 30.  
There is an ongoing drive to replace, reduce and refine the use of animals, particularly higher 
species. Using a novel matrix design we were able to screen a larger number of routes and adjuvants 
in a species that is more predictive of the responses in the clinic, thereby reducing animal usage and 
refining the quality of data produced. The importance of using an animal species closer to man is 
underlined by the difference between the immune response to mucosal vaccination and adjuvants 
observed in macaques and previously published data from mouse models. In our previous studies 
we have observed that R848 was a less potent adjuvant than the synthetic TLR4 ligand GLA 31 and 
range of other TLR based adjuvants 8 when delivered intranasally in mice, though other groups have 
observed a boost to antibody responses when R848 was delivered intranasally 32. Likewise as 
described above, sublingual immunisation is extremely effective in mice, but appears to have limited 
immunogenicity in the macaque study we performed here. The difference between species will be 
driven by a range of factors including anatomy, pattern recognition receptor expression patterns and 
response, for example mice do not have a functional TLR8 molecule 33. We believe there is still a role 
for mouse models in the initial screen for vaccines, particularly for the dissection of immune 
response and challenge models, but they are poorly predictive of adjuvant strategies effective for 
mucosal immunisation in non-human primates and most likely also in humans.  
This study was designed to maximise the number of adjuvants screened and the routes tested, 
whilst minimising the number of animals used in order to select products for clinical trials. As such 
there some limitations to the interpretation of the results, which would need to be addressed in 
order to fully define mechanisms of action. The adjuvants were selected based on our previous small 
animal studies, the availability of GMP products (to accelerate clinical trials) and literature review 5 
but ideally, more adjuvants would have been tested, for example comparing intranasal Poly(I:C) and 
R848 as both work via endocytic TLR. Due to repeat usage in the same animals, different antigens 
had to be used for the different routes. The antigens were chosen as they are common experimental 
antigens, widely used in other studies, but they may have different immunogenicity in macaques. 
Our previous experience with intrarectal immunisation in mice suggests this route is poorly 
immunogenic 34. The results from this study suggest sublingual delivery of antigen is poorly 
immunogenic, but further studies with different antigens delivered sublingually are required to 
confirm our findings. Another limitation to the design of the study is that the close proximity of the 
immunisations may have altered the outcomes of subsequent immunisations, we don’t anticipate 
original antigenic sin as the antigens are structurally diverse, but there may have been some 
hangover effect of the inflammation from the adjuvants, which we have seen in previous studies 35. 
However, given the lack of response to sublingual or intrarectal delivered antigen, this seems to 
have been minimal. Finally in the follow up studies comparing intramuscular with intranasal R848, 
the animals used had been previously exposed to KLH intranasally with the adjuvants that had not 
induced a response (4 with PBS, 4 with Pam3CSK4). The animals were randomised into the follow up 
study, but there may have been some priming. In conclusion, in the current study, we successfully 
screened a number of mucosal adjuvants, demonstrating that R848 was safe and effective, 
suggesting it could be taken forward into phase I clinical trials for intranasally delivered antigen after 
appropriate toxicity studies. 
Methods and Materials 
Reagents 
Adjuvants: TLR ligands Pam3CSK4 (TLR1/2), Poly(I:C) (TLR3), R848 (TLR7/8) (InvivoGen), 
Monophosphoryl Lipid A (MPLA, TLR4) (Sigma-Aldrich), human Thymic Stromal Lymphopoietin 
(ProSpec) and chitosan (NovaMatrix).  
Antigens: EndoGrade Keyhole Limpet Haemocyanin (Calbiochem), Ovalbumin (Hyglos GmbH) and β-
galactosidase (ProZyme Inc.). 
Animals and Ethics Statement 
Rhesus macaques (Macaca mulatta) were obtained from and housed at the Tulane National Primate 
Research Center. The Institutional Animal Care and Use Committee (IACUC) of Tulane University 
approved all macaque procedures described (protocol permit number P0031). In this study all 
procedures were carried out in strict accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health (NIH) and with the 
recommendations of the Weatherall report; “The use of non-human primates in research”. All 
procedures were performed under anaesthesia using ketamine, and all efforts were made to 
minimise stress, improve housing conditions, and to provide enrichment opportunities (e.g., objects 
to manipulate in cage, varied food supplements, foraging and task-oriented feeding methods, 
interaction with caregivers and research staff).  
Macaque plasma samples were shipped to the UK, under strict accordance of The Convention on 
International Trade in Endangered Species (CITES). Permits were obtained from the US Fish and 
Wildlife Service and the Department of Environment, Food, and Rural Affairs (DEFRA), UK. The 
samples were stored at -80°C until further use.  
Antigen and Route of Immunisation 
Female Rhesus macaques (n=4 per group) were treated with an intramuscular injection of 
depomedroxyprogesterone acetate (Depo-Provera) (30 mg) 4 weeks prior to first administration. For 
each route, immunisations were performed in a staggered regime every four weeks according to the 
schedule in Table 1. The same animals were used for all three routes tested, with one week gaps 
between each route of delivery. Animals were immunised intranasally (IN), with KLH at a dose of 200 
µg in a volume of 200 μl per nostril (400 μl total), intrarectally (IR) with 200 µg β-Gal in a volume of 4 
ml or sublingually (s.l.) with 225 µg OVA in a volume of 200 μl per each side of the tongue (400 μl 
total) (Table 2).  
Six different adjuvants were assessed (Table 2); PBS (control), Pam3CSK4, MPLA, Poly(I:C), chitosan 
and R848. Pam3CSK4, MPLA, Poly(I:C), TSLP, and R848 (Resiquimod) were used at 500 µg per dose 
for all routes of administration, chitosan was used at 1%. All immunisations were administered in 
PBS. 
Following the initial study, animals (in two groups of four animals, n=4), were immunised either IN or 
intramuscularly (IM) with KLH+R848 at the same concentrations as in the previous study, at weeks 0, 
4 and 8.  
Macaque Samples 
Blood samples were taken once a week from week 0 to week 16 for determination of systemic 
antibody levels. 10 ml EDTA anti-coagulated blood was collected at each timepoint and separated 
into plasma. Cervical, nasal, rectal and sublingual/saliva fluid samples were taken to determine 
mucosal antibody levels at week 0, then once weekly from week 4 to week 16. All fluid samples were 
frozen at – 80°C and centrifuged before testing, in addition the plasma samples were heat-treated at 
56°C for 30 min prior to centrifugation to remove any non-specific complement activation. 
For mucosal fluid collections, animals were first sedated using ketamine hydrochloride, and then 
secretions were sampled from all tissues using pre-weighed, pre-wet Weck-cel surgical spears 
(Medtronic Ophthalmics) placed in each site for 5 min. For vaginal secretions, two pre-wet Weck-cel 
spears were placed in the vaginal vault; for sublingual saliva samples, a pre-moistened sponge was 
placed sublingually; for rectal samples two sponges were gently inserted into the rectum and nasal 
samples were collected by inserting one Weck-cel sponge into each nare. 
For all samples, Weck-cel sponges were removed after 5 min, reweighed, and secretions were eluted 
from the sponges by placing each spear into the upper chamber cup of a Spin-X tube (Corning) to 
which 300 µl of a hypertonic extraction buffer containing sodium azide (preservative) and protease 
inhibitors (protease inhibitor cocktail set 1, Calbiochem Merck) was added. Samples were incubated 
for 10 min on ice, then spun for 15 min at 15,000 RPM, after which the filter cup and sponge were 
discarded, and the fluid in the bottom chamber was frozen and stored at -80°C until analysis.  
Detection of Specific and Total Immunoglobulins 
Specific immunoglobulin concentrations in plasma and mucosal samples were measured by 
sandwich ELISA, adapted from a gp-140 specific ELISA developed by our laboratory 36. 96-well plates 
(medium binding, Greiner Bio-One, UK) were coated with specific antigen (KLH, OVA or β-gal), 
(5µg/ml). After washing with 0.05% PBS-Tween 20 (PBST), (Tween-20, Fisher Scientific) and blocking 
with assay buffer (10% FBS-PBST) (FBS, Gibco®-Life Technologies), plasma samples were added at 
1/100 and mucosal at 1/20 dilutions, in triplicate. Bound immunoglobulin was detected by addition 
of goat anti- monkey IgG (Fc-specific) HRP conjugate (AbD Serotec) or goat anti-monkey (-specific) 
– biotin conjugate (ACRIS) followed by avidin – peroxidise detection antibody. Plates were read at 
450 nm on a VersaMax™ microplate reader, after addition of SureBlue TMB substrate (KPL) followed 
by 1N H2SO4 to stop the colorimetric reaction. Endpoint titres were calculated from raw data using 
SoftMax Pro® software (Molecular Devices) and GraphPad Prism 5 as the reciprocal of the highest 
dilution giving an absorbance value equal or higher to the background (normal rhesus macaque 
plasma) plus two standard deviations. Cut-off value was set at 0.2.  
Relative coefficients of excretion 
Albumin levels were detected in plasma, nasal and vaginal samples using a Human Albumin Elisa kit 
as per manufacturer’s instructions (Bethyl Labs Inc.). The relative coefficients of excretion (RCE) was 
calculated according to the formula: [(Immunoglobulin (Ig) in fluid)/ (Human serum albumin (HAS) in 
fluid)]/ [(Ig in serum)/(HSA in serum)] 11. Calculations were performed based on titres of Ig, not 
absolute concentration values. 
Secretory IgA levels 
Secretory IgA (scIgA) levels were determined using a sandwich ELISA, as detailed above for the 
specific antigen ELISA. Plates were coated with specific antigen, prior to the addition of samples. 
Detection of scIgA was achieved using a biotin-conjugated IgG antibody specific to monkey secretory 
component, (Nordic Immunological Laboratories), at 1/20 dilution, followed by detection by HRP-
streptavidin. 
Inflammatory profile of intranasal R848  
Following completion of the above experiments, 20 of the animals selected from the above 
experiment were briefly re-used in experiments to assess safety of nasal R848 administration. Then, 
15 animals received an intranasal inoculation with 500 µg R848 in 400 μl PBS (200 μl per nostril), and 
5 controls were treated with PBS alone. One nasal swab was collected from each nare at time 0, 1, 2, 
3, 4, 6, 8, 24, 48, and 96 hrs. One swab was immersed and eluted in 1 ml sterile PBS for determining 
cellular infiltrates by flow cytometry and manual cytospin counts, and the other was processed in 
the extraction buffer as described above for assessing cytokine/chemokine responses by multiplex 
bead array.  
For cell counts, 200 μl aliquots of cells that were eluted in PBS were cytospun onto glass slides and 
stained with a Wrights stain for manual cell counts, and counted by a pathologist. The remaining 
cells were stained with anti-CD3, CD4, CD8, and CCR5 monoclonal antibodies, and analysed by flow 
cytometry.  
For multiplex cytokine bead arrays (CBA, Becton Dickinson), nasal fluid was incubated with beads 
pre-conjugated to anti-cytokine/chemokine antibodies against IL-1β, IL-2, IL-6, CXCL8/IL-8, 
CCL3/MIP-1α, CCL4/MIP-1β, G-CSF, GM-CSF, CCL5/RANTES, CCL2/MCP-1, TNF, and IFN- and 
analysed using a FACS Array bioanalyzer (Becton Dickinson). 
Statistical analysis 
Comparisons of two groups were performed using Student’s t tests. Comparisons of multiple groups 
were performed using one- or two-way ANOVA with appropriate post-tests. All statistical tests were 
performed using GraphPad Prism version 6.01 for Windows (GraphPad Software). 
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Figure Legends 
Figure 1. R848 is a potent mucosal adjuvant. Macaques were immunised intranasally with 200 μg 
KLH in combination with 500 μg of the adjuvants R848, Pam3SCK4 or chitosan, or 50 μg of TSLP or in 
PBS alone (n=4 per group). Immunisations were administered at weeks 0, 4 and 8. KLH specific IgG 
was measured in plasma for all groups (A). Further analysis was performed for animals IE73, IE74, 
GK02 and IF53 from the R848/ KLH group and IE71 from the TSLP group. KLH specific ELISA were 
performed for IgG (C, E) and IgA (B, D, F) on plasma (B), nasal wash (C, D) and vaginal Weck-cels (E, 
F). KLH specific scIgA was measured in nasal samples (G). Relative coefficients of excretion (RCE) 
compared to albumin in nasal and vaginal samples (H). Data is presented as mean +/- SD of n=4 
animals (A, H) or individual animals (B-G). 
Figure 2. R848 induces antibody responses after mucosal or systemic immunisation. Macaques 
were immunised intramuscularly (IM, open symbols, A, B) or intranasally (IN, closed symbols, C, D) 
with 200 μg KLH in combination with 500 μg R848 (n=4 per group). Immunisations were 
administered at weeks 0, 4 and 8. KLH specific ELISA were performed for IgG (A, C) and IgA (B, D) in 
plasma, data is presented as individual animals. Pooled data for each route is presented for IgG (E) 
and IgA (F), where each point represents mean of the n=4 animals presented in A-D. * p<0.05, ** 
p<0.01 by multiple weighted t-test. 
Figure 3. R848 induces local antibody responses after mucosal or systemic immunisation. 
Macaques were immunised intranasally (A, E, I) or intramuscularly (B, F, J) with 200 μg KLH in 
combination with 500 μg R848 (n=4 per group). Immunisations were administered at weeks 0, 4 and 
8. KLH specific ELISA were performed for IgG (A, B, C) and IgA (E, F, G) in nasal lavage and IgG in 
vaginal samples (I,J,K). Relative coefficients of excretion (RCE) compared to albumin in nasal and 
vaginal samples (D, H, L). Data is presented as individual animals. Pooled data for each route is 
presented for each sample (C, F, I), where each point represents mean of n=4 animals. 
Figure 4. R848 induces mild local inflammation. Macaques were immunised intranasally with R848 
or PBS and Nasal swabs collected at time 0, 1, 2, 3, 4, 6, 8, 24, 48, and 96 hrs. Nasal swabs examined 
for cellular infiltrates, neutrophils by cytospin (A), monocytes (B) and CD3 cells (C) by flow cytometry 
and fluids for cytokine/chemokine responses by CBA (D-I). Points represent n= 15 animals in the 
R848 group and 5 animals in the PBS control group + SEM, * p<0.05 by multiple weighted t test. 
  
Table 1. Dosing schedule. 
  WK -4 WK 
0 
WK 
1 
WK 
2 
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3 
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4 
WK 
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WK 
6 
WK 
7 
WK 
8 
WK 
9 
WK 
10 
Depo-Provera √                       
Immunisation                         
Nasal   √       √       √     
Rectal     √       √       √   
Sublingual       √       √       √ 
 
 
Table 2. Antigen, adjuvant and route. 
  Animal ID IE57, IE58, 
IE59, IE60 
IE61, IE62, 
IE63, IE64 
IE65, IE66, 
IE67, IE68 
IE69, IE70, 
IE71, IE72 
IE73, IE74, 
GK02, IF53 
Antigen Route  Adjuvant 
Keyhole Limpet 
Haemocyanin (KLH) 
Intranasal PBS Pam3CSK4 Chitosan TSLP R848 
Ovalbumin (Ova) Sublingual Poly(I:C) Chitosan R848 PBS Pam3CSK4 
Beta-galactosidase 
(β-Gal) 
Intrarectal R848 Poly(I:C) PBS Pam3CSK4 MPLA 
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